latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/sinopharm-group-fy-19-profit-up-7-1-revenue-rises-23-4-57807575 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Sinopharm Group FY'19 profit up 7.1%; revenue rises 23.4%

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Sinopharm Group FY'19 profit up 7.1%; revenue rises 23.4%

Shanghai-based Sinopharm Group Co. Ltd.'s profit for full-year 2019 grew 7.1% year over year, while revenue rose 23.4%.

Profit attributable to equity holders of the parent for the year reached 6.25 billion Chinese yuan, up from 5.84 billion yuan in 2018.

Diluted EPS was 2.10 yuan, up from 1.96 yuan in the previous year.

Revenue for the year ended Dec. 31, 2019, was 425.27 billion yuan, up from 344.53 billion yuan a year earlier.

Sinopharm, a wholesaler and retailer of pharmaceutical and healthcare products, booked 2019 operating profit of 16.14 billion yuan, up from 14.07 billion yuan in 2018.

Due to disruptions caused by the COVID-19 pandemic, Sinopharm said its board expects the company's performance for the first quarter ending March 31 may decline on a year-on-year basis.

As of March 27, US$1 was equivalent to 7.10 Chinese yuan.